Alternative interferons and immunomodulators in the treatment of hepatitis C

Authors

  • Hawwa Alao,

    1. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Search for more papers by this author
  • T. Jake Liang

    Corresponding author
    1. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    • Correspondence

      T. Jake Liang, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 10-9B16, 10 Center Dr., Bethesda, MD 20892, USA

      Tel: +1 301 496 1721

      Fax: +1 301 402 0491

      e-mail: jakel@bdlg10.niddk.nih.gov

    Search for more papers by this author

Abstract

Interferon-α (IFN-α) has been the mainstay of therapy for hepatitis C and is currently being combined with other drugs to improve the response rate. Newer therapeutic regimens are being developed to spare the use of IFN because of the important side effects associated with IFN-based therapy. However, there may still be a need for the use of IFN in certain populations. In addition, agents that mimic the actions of IFN but with fewer side effects may still be of major value. This review focuses on the development of alternative and new forms of IFNs and other immunomodulatory agents that may supplant IFN-α in combination therapy for hepatitis C.

Ancillary